At the highest downstream specification, Sanhuang Shuangding Injection Veterinary Grade API is processed into a sterile parenteral solution for swine and bovine respiratory–enteric complex. The receiving lot is first assayed for berberine hydrochloride and baicalin by HPLC using a C18 column and a pH-buffered acetonitrile gradient; only lots with chromatographic purity not less than 0.90 similarity factor against the reference extract lot are released into the sterile suite. A pilot-scale 316L stainless steel jacketed vessel with bottom-mounted magnetic impeller is used to dissolve the API in Water for Injection at 40°C to 50°C; the concentrate is prepared at 1 part API to 9 parts WFI to reduce solvent shock, then diluted to final batch volume. After cooling, the solution is adjusted to pH 5.5–6.5 with citric acid–sodium citrate buffer, because alkaline conditions above pH 7.0 accelerate hydrolysis of anthraquinone glycosides. Activated carbon at 0.1% w/v is applied under slow agitation for 20 min to remove pyrogens and high-molecular-weight tannin fractions; the carbon is removed through a 0.45 µm PVDF prefilter, and the clear filtrate is terminally sterilized through a 0.22 µm PVDF sterilizing-grade filter. Filled vials are autoclaved at 121°C for 15 min; post-cycle recovery of berberine chloride must remain not less than 95% of the pre-sterilization value. The finished dosage form is filled into 10 mL amber glass ampoules or vials and released against USP <71> sterility, USP <85> bacterial endotoxins, and USP <788> particulate matter. This route is incompatible with saline or Ringer’s diluents containing divalent cations, as polyphenol fractions can precipitate; published data for the specific autoclave degradation profile in this configuration is limited, so each new batch requires a short thermal challenge study.

Process water quality is a second limitation. Reverse osmosis permeate with conductivity below 1.3 µS/cm and total organic carbon below 500 ppb is used, because trace iron or copper ions catalyze polyphenol oxidation. Batch-to-batch variation of raw extract color and insoluble matter is controlled by a pre-dissolution centrifugation step at 3,000 × g for 5 min before sterile filtration. Pharmaceutical manufacturers using this API in injectable form frequently run a filter compatibility study with PVDF, PES, and nylon membranes; rejection of active markers can exceed 10% on nylon due to electrostatic adsorption, and PVDF is preferred. The terminal solution may show slight opalescence after autoclaving; if turbidity exceeds 3 NTU, the batch is rejected. These operating boundaries apply to the injectable grade only; a failed pyrogen or sterile filtration attempt cannot be corrected by re-designation to oral use without a documented deviation and full re-processing validation.

What Limits Recoverable Baicalin in Poultry Water Premixes?

In water-soluble powder and medicated premix applications, the API is formulated as a low-moisture carrier-based blend for reconstitution through proportioner or tank dilution at poultry farms. The primary process conflict is dissolved-oxygen and alkaline pH degradation of baicalin in liner materials and in hard water. Finished water premix batches are therefore kept below pH 5.0 at the point of reconstitution by adding anhydrous citric acid at 0.5–1.0% w/w of final premix, and the carrier is dried to a loss on drying below 5.0% before blending. A representative production run uses a 500 L ribbon blender with counter-rotating blades at 25 rpm for 15 min; the API is first triturated with colloidal silicon dioxide at 1:1 ratio to neutralize electrostatic cake formation, then geometrically diluted into anhydrous glucose monohydrate in three stages. The terminal blend is screened through a 60-mesh sieve and filled into 100 g or 500 g aluminium-foil laminated sachets. Process water for farm-side dilution should have hardness not exceeding 250 mg/L CaCO₃, and the stock solution should be used within 24 h to limit oxidative loss. Aerobic total plate count is controlled according to USP <61>, and absence of Salmonella is confirmed using ISO 6579-1:2017; heavy metals are reported by ICH Q3D-aligned ICP-MS. The resulting end product is a free-flowing yellow-brown powder that yields a clear-to-slightly opalescent solution at 1 kg per 1,000 L of drinking water.

For a lot release decision, the following test matrix is applied to water premix and the other finished forms described in this section.

Ruminant Tablet Compression, Disintegration, and Bolus Geometry

For oral dosing in ruminants and pigs, the API is converted into tablets or large cylindrical boluses by wet granulation. The extract powder has poor plastic deformation and requires a dry binder; microcrystalline cellulose is used at 15–20% w/w, and povidone K30 is dissolved in anhydrous ethanol to a final binder concentration of 2–5% w/w dry mass. Granulation is performed in a high-shear mixer-granulator with impeller speed 200–300 rpm and chopper speed 1,200 rpm; the endpoint is reached when wet mass passes the squeeze test but shows no free surface water, corresponding to typical granulate moisture of 8–12% by loss on drying. Drying is performed in a fluid-bed dryer with inlet air temperature 55–60°C; product temperature must not exceed 45°C to avoid degradation of berberine-related alkaloids. The dried granules are blended with crospovidone at 3% w/w and magnesium stearate at 0.5% w/w before compression on a rotary tablet press of 12–16 kN compression force for 1 g tablets. Hardness is monitored at 60–100 N and disintegration is tested using USP <701> in 900 mL water at 37°C; the acceptance criterion is complete disintegration within 30 min.

For adult cattle, the same granulate is compressed into a 5 g elongated bolus with a score line, requiring a larger die and lower dwell time; bolus hardness is limited to 80–120 N to prevent esophageal impaction. The finished tablets are coated with a hydroalcoholic shellac coating to reduce moisture pickup. The finished product is tested under USP <1216> for friability and USP <786> for particle size distribution of granules. Stability under accelerated conditions at 40°C/75% RH for 6 months must show no significant discoloration or failure of disintegration, following VICH GL3; a moisture-barrier primary package is mandatory in humid climates.

Encapsulation is preferred when the final veterinary product is dispensed in unit-dose form for swine, sheep, or companion animal veterinary hospitals. The API is reduced to a fine powder with not less than 95% passing 80 mesh; due to hygroscopicity, direct filling is avoided unless the ambient relative humidity is maintained below 45%. Dry granulation by slugging or roller compaction is used to densify the extract powder and improve flow into metering-type capsule fillers. A typical slugging blend contains API at 20% w/w, dicalcium phosphate dihydrate at 65% w/w, crospovidone at 5% w/w, and talc at 1% w/w. Slugs are milled through a 1.0 mm stainless steel screen and passed through a 30-mesh sieve. The granulate is filled into size 0 hard gelatin capsules to a target fill weight of 500 mg; fill weight variability is controlled within ±3% by in-process checkweighing. Dissolution testing is performed using USP <711>; the medium is 0.1 N hydrochloric acid at 37°C, and the release of berberine chloride is monitored by HPLC. Capsule shells should be stored in a moisture-tight container; exposure to relative humidity above 60% causes shell cross-linking and delayed rupture. The terminal product is a two-piece hard capsule or a sealed liquid-free unit for oral administration. For use in non-ruminant species, the capsule content may be mixed with soft feed; however, mixing with hot feed above 45°C is prohibited because alkaloid recovery declines rapidly.

Granulated forms are used where the final product must be dispersible in water or feed and where dusting must be minimized. The API is formulated as effervescent-free granules by fluid-bed top spray. A binder solution of polyvinylpyrrolidone K30 at 4% w/w total solids in anhydrous ethanol is sprayed onto a fluidized mixture of API (8% w/w), maltodextrin (60% w/w), sucrose (25% w/w), and citric acid (2% w/w). The fluid-bed dryer is operated with inlet air temperature 60°C and product temperature 38–42°C; spray rate is adjusted to 20 g/min per 10 kg batch to maintain granule growth below 1.5 mm. After spraying, the material is dried until loss on drying is below 4.0% and then sieved; the target granule size is 20–60 mesh. The final granules are filled into 200 g polyethylene bottles with induction-sealed caps. Bulk density is measured by USP <616> and should remain within 0.55–0.75 g/mL to ensure uniform volumetric dosing. The product is diluted in water at 20 g per 10 L of drinking water under continuous agitation; water temperature above 30°C reduces powder wetting and may require a pre-slurry step. Aerobic microbial counts are controlled to USP <61> limits, and the absence of Escherichia coli is confirmed by ISO 16649-2:2001.

Oral Solution Stability Depends on Preservative Compatibility, Not Just Solubility

Liquid oral solutions and drenches represent a separate downstream route where the API is fully dissolved or dispersed to form a uniform low-volume dose for calves, foals, and swine. A preservative system is selected before finalizing the solvent ratio because the extract contains reducing polyphenols that can inactivate benzoate-based preservatives. The oral solution is formulated at 8% w/v API in a cosolvent system of purified water and propylene glycol (60:40 v/v); after hydration for 30 min under low-shear stirring, a high-shear rotor-stator mixer is used at 3,000 rpm for 10 min to reduce insoluble tannin agglomerates. The solution is buffered to pH 4.0–4.5 with acetate buffer, and potassium sorbate is added at 0.3% w/v; stability data indicate that pH above 5.0 accelerates sorbate oxidation in the presence of light. The batch is passed through a 50 µm nylon screen before filling into 50 mL or 100 mL amber PET bottles with tamper-evident caps. Accelerated stability is evaluated at 40°C/75% RH for 6 months following VICH GL3 guidance, with HPLC marker recovery required to remain not less than 90% of initial. The finished drench is drawn into an oral dosing gun; the correct fill volume is verified by weight at ±1.5% tolerance. The product is not autoclavable; it is preserved and must be used within 28 days after first opening.

Compatibility with nitrofuran or sulfonamide co-medications is not assumed. The oral solution should not be diluted with chlorinated farm water above 4 ppm free chlorine because residual chlorine reacts with the polyphenolic fraction. Storage below 2°C may cause precipitation of poorly soluble aglycones; the product should be warmed to room temperature and shaken before use. The bottle headspace is purged with nitrogen during filling to keep dissolved oxygen below 2 mg/L.